D. Papa, N. Zaccara, and E. , From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis, Best Pract Res Clin Rheumatol, vol.29, issue.6, pp.756-69, 2015.

J. Fransen, D. Popa-diaconu, R. Hesselstrand, P. Carreira, G. Valentini et al., Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres, Annals of the Rheumatic Diseases, vol.70, issue.10, pp.1788-92, 2011.

K. M. Sullivan, E. A. Goldmuntz, L. Keyes-elstein, P. A. Mcsweeney, A. Pinckney et al., Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma, N Engl J Med, vol.378, issue.1, pp.35-47, 2018.

J. M. Van-laar, D. Farge, J. K. Sont, K. Naraghi, Z. Marjanovic et al., Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial, JAMA. 25 juin, vol.311, issue.24, pp.2490-2498, 2014.

R. K. Burt and D. Farge, Systemic sclerosis: Autologous HSCT is efficacious, but can we make it safer?, Nat Rev Rheumatol, vol.14, issue.4, pp.189-91, 2018.

L. Da-silva-meirelles, Mesenchymal stem cells reside in virtually all post-natal organs and tissues, Journal of Cell Science. 9 mai, vol.119, issue.11, pp.2204-2217, 2006.

P. Rozier, A. Maria, R. Goulabchand, C. Jorgensen, P. Guilpain et al., Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use?, Front Immunol, vol.9, p.2938, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02304369

Y. Wu, S. Huang, J. Enhe, K. Ma, S. Yang et al., Bone marrow-derived mesenchymal stem cell attenuates skin fibrosis development in mice, Int Wound J. déc, vol.11, issue.6, pp.701-711, 2014.

A. Bronckaers, P. Hilkens, W. Martens, P. Gervois, J. Ratajczak et al., Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis, Pharmacol Ther. août, vol.143, issue.2, pp.181-96, 2014.

X. Liang, Y. Ding, Y. Zhang, H. Tse, and Q. Lian, Paracrine Mechanisms of Mesenchymal Stem Cell-Based Therapy: Current Status and Perspectives, Cell Transplant. sept, vol.23, issue.9, pp.1045-59, 2014.

S. H. Lee, E. J. Lee, S. Y. Lee, J. H. Kim, J. J. Shim et al., The effect of adipose stem cell therapy on pulmonary fibrosis induced by repetitive intratracheal bleomycin in mice, Experimental Lung Research. 16 mars, vol.40, issue.3, pp.117-142, 2014.

M. Uji, Y. Kureya, K. Yamada, T. Watanabe, K. Konishi et al., Effect of intratracheal administration of adipose-derived stromal cells on bleomycin-induced lung injury in a rat model, 33 Mechanisms of Lung Injury and Repair

, , p.943, 2015.

J. Tashiro, S. J. Elliot, D. J. Gerth, X. Xia, S. Pereira-simon et al., Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis, Translational Research. déc, vol.166, issue.6, pp.554-67, 2015.

A. Maria, K. Toupet, C. Bony, N. Pirot, M. Vozenin et al., Antioxidant, and Immunomodulatory Effects of Mesenchymal Stem Cells in HOCl-Induced Systemic Sclerosis: MESENCHYMAL STEM CELLS IN MURINE SSc, vol.68, pp.1013-1038, 2016.

N. Scuderi, S. Ceccarelli, M. G. Onesti, P. Fioramonti, C. Guidi et al., Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis, Cell Transplant, vol.22, issue.5, pp.779-95, 2013.

M. G. Onesti, P. Fioramonti, S. Carella, P. Fino, C. Marchese et al., Improvement of Mouth Functional Disability in Systemic Sclerosis Patients over One Year in a Trial of Fat Transplantation versus Adipose-Derived Stromal Cells, Stem Cells Int, p.2416192, 2016.

B. Granel, A. Daumas, E. Jouve, J. Harlé, P. Nguyen et al., Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial, Ann Rheum Dis. déc, vol.74, issue.12, pp.2175-82, 2015.

A. Daumas, J. Magalon, E. Jouve, R. Truillet, D. Casanova et al., Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients, Curr Res Transl Med. mars, vol.65, issue.1, pp.40-43, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01792172

D. Benedetto, P. Cipriani, P. Ruscitti, P. Liakouli, V. Giacomelli et al., Adipose stromal vascular fraction and regenerative therapy in SSc: response to the article by Magalon et al, Ann Rheum Dis. 2 févr, 2019.

J. Magalon, M. Velier, S. Simoncini, F. Dignat-george, B. Granel et al., Response to: « Adipose stromal vascular fraction and regenerative therapy in SSc: response to the article by Magalon et al, Ann Rheum Dis. 20 févr, 2019.

M. Manetti, Could autologous adipose-derived stromal vascular fraction turn out an unwanted source of profibrotic myofibroblasts in systemic sclerosis?, Ann Rheum Dis. 13 mars, 2019.

M. Velier, J. Magalon, S. Simoncini, F. Dignat-george, B. Granel et al., Response to: « Could autologous adipose-derived stromal vascular fraction turn out an unwanted source of profibrotic myofibroblasts in systemic sclerosis? » by Manetti, Ann Rheum Dis. 9 avr, 2019.

D. Benedetto, P. Panzera, N. Cipriani, P. Mastroiaco, V. Tessitore et al., Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling, Sci Rep. 9 mai, vol.9, issue.1, p.7144, 2019.

R. Lee, D. Papa, N. Introna, M. Reese, C. F. Zemskova et al., Adipose-derived mesenchymal stromal/stem cells in systemic sclerosis: Alterations in function and beneficial effect on lung fibrosis are regulated by caveolin-1, Journal of Scleroderma and Related Disorders. juin, vol.4, issue.2, pp.127-163, 2019.

F. Virzì, P. Bianca, A. Giammona, T. Apuzzo, D. Franco et al., Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patients, Stem Cell Res Ther, vol.8, issue.1, p.236, 2017.

B. Delorme and P. Charbord, Culture and characterization of human bone marrow mesenchymal stem cells, Methods Mol Med, vol.140, pp.67-81, 2007.

S. Viau, L. Chabrand, S. Eap, J. Lorant, K. Rouger et al., Pathogen reduction through additivefree short-wave UV light irradiation retains the optimal efficacy of human platelet lysate for the expansion of human bone marrow mesenchymal stem cells, PLoS ONE, vol.12, issue.8, p.181406, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01524322

T. Korff, S. Kimmina, G. Martiny-baron, and A. Hg, Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness, FASEB J. févr, vol.15, issue.2, pp.447-57, 2001.

J. Eglinger, H. Karsjens, and E. Lammert, Quantitative assessment of angiogenesis and pericyte coverage in human cell-derived vascular sprouts, Inflamm Regen, vol.37, issue.2, 2017.

B. Delorme, J. Ringe, N. Gallay, L. Vern, Y. Kerboeuf et al., Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells, Blood. 1 mars, vol.111, issue.5, pp.2631-2636, 2008.

M. Dominici, L. Blanc, K. Mueller, I. Slaper-cortenbach, I. Marini et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, Cytotherapy, vol.8, issue.4, pp.315-322, 2006.

J. Larghero, D. Farge, A. Braccini, S. Lecourt, A. Scherberich et al., Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis, Ann Rheum Dis. avr, vol.67, issue.4, pp.443-452, 2008.

M. Griffin, C. M. Ryan, O. Pathan, D. Abraham, C. P. Denton et al., Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine, Stem Cell Res Ther, vol.07, issue.1, p.23, 2017.

C. Capelli, E. Zaccara, P. Cipriani, D. Benedetto, P. Maglione et al., Phenotypical and Functional Characteristics of In Vitro-Expanded Adipose-Derived Mesenchymal Stromal Cells From Patients With Systematic Sclerosis, Cell Transplant, vol.09, issue.5, pp.841-54, 2017.

V. Turinetto, E. Vitale, and C. Giachino, Senescence in Human Mesenchymal Stem Cells: Functional Changes and Implications in Stem Cell-Based Therapy, IJMS. 19 juill, vol.17, issue.7, p.1164, 2016.

P. Cipriani, D. Benedetto, P. Liakouli, V. , D. Papa et al., Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (T reg s ) with a functional phenotype: implications for cellular-based therapy: SSc-MSC preserve immunomodulatory abilities, Clin Exp Immunol. août, vol.173, issue.2, pp.195-206, 2013.

A. E. Wyman and S. P. Atamas, Sirtuins and Accelerated Aging in Scleroderma, Curr Rheumatol Rep, vol.20, issue.4, p.16, 2018.

J. Magalon, M. Velier, S. Simoncini, P. François, B. Bertrand et al., Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis, Ann Rheum Dis. mars, vol.78, issue.3, pp.391-399, 2019.

P. Cipriani, D. Benedetto, P. Ruscitti, P. Liakouli, V. Berardicurti et al., Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis, J Rheumatol, vol.43, issue.7, pp.1340-1349, 2016.

P. A. Nicolosi, E. Tombetti, N. Maugeri, P. Rovere-querini, S. Brunelli et al., Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis, Stem Cells Int, p.4636859, 2016.

A. Almadori, M. Griffin, C. M. Ryan, D. F. Hunt, E. Hansen et al., Stem cell enriched lipotransfer reverses the effects of fibrosis in systemic sclerosis, PLoS ONE, vol.14, issue.7, p.218068, 2019.

M. Manetti, E. Romano, I. Rosa, B. S. Fioretto, E. Praino et al., Systemic Sclerosis Serum Steers the Differentiation of Adipose-Derived Stem Cells Toward Profibrotic Myofibroblasts: Pathophysiologic Implications, J Clin Med. 19 août, vol.8, issue.8, 2019.

T. Nenasheva, A. Nikolaev, D. Diykanov, A. Sukhanova, E. Tcyganov et al., The introduction of mesenchymal stromal cells induces different immunological responses in the lungs of healthy and M. tuberculosis infected mice. Olszewski MA, éditeur, PLoS ONE. 8 juin, vol.12, issue.6, p.178983, 2017.

J. Barnes and M. D. Mayes, Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers, Curr Opin Rheumatol, vol.24, pp.165-170, 2012.

B. Ranque and L. Mouthon, Geoepidemiology of systemic sclerosis, Autoimmun Rev, vol.9, pp.311-318, 2010.

E. Hachulla and D. Launay, Diagnosis and classification of systemic sclerosis, Clin Rev Allergy Immunol, vol.40, pp.78-83, 2011.

F. D'amico, E. Skarmoutsou, and M. C. Mazzarino, The sex bias in systemic sclerosis: on the possible mechanisms underlying the female disease preponderance, Clin Rev Allergy Immunol, vol.47, pp.334-343, 2014.

M. Elhai, C. Meune, J. Avouac, A. Kahan, and Y. Allanore, Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies, Rheumatology (Oxford), vol.51, pp.1017-1026, 2012.

M. D. Mayes, Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population, Arthritis Rheum, vol.48, pp.2246-2255, 2003.

M. Elhai, Mapping and predicting mortality from systemic sclerosis, Ann. Rheum. Dis, vol.76, pp.1897-1905, 2017.

D. Godard, The needs of patients with systemic sclerosis--what are the difficulties encountered?, Autoimmun Rev, vol.10, pp.291-294, 2011.

Y. Allanore, P. Dieude, and C. Boileau, Genetic background of systemic sclerosis: autoimmune genes take centre stage, Rheumatology (Oxford), vol.49, pp.203-210, 2010.

C. Feghali-bostwick, T. A. Medsger, and T. M. Wright, Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies, Arthritis Rheum, vol.48, pp.1956-1963, 2003.

T. S. Rodriguez-reyna, HLA Class I and II Blocks Are Associated to Susceptibility, Clinical Subtypes and Autoantibodies in Mexican Systemic Sclerosis (SSc) Patients, PLoS ONE, vol.10, p.126727, 2015.

H. Furukawa, Human Leukocyte Antigen and Systemic Sclerosis in Japanese: The Sign of the Four Independent Protective Alleles, PLoS ONE, vol.11, p.154255, 2016.

Y. Xu, W. Wang, Y. Tian, J. Liu, and R. Yang, Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta-analysis, Int. J. Dermatol, vol.55, pp.408-416, 2016.

N. Altorok and B. Kahaleh, Epigenetics and systemic sclerosis, Semin Immunopathol, vol.37, pp.453-462, 2015.

I. Marie and J. Gehanno, Environmental risk factors of systemic sclerosis, Semin Immunopathol, vol.37, pp.463-473, 2015.

I. Marie, Association of occupational exposure with features of systemic sclerosis, J Am Acad Dermatol, vol.72, pp.456-464, 2015.

I. Marie, Systemic sclerosis and exposure to heavy metals: A case control study of 100 patients and 300 controls, Autoimmun Rev, vol.16, pp.223-230, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02109413

A. Kettaneh, Occupational exposure to solvents and gender-related risk of systemic sclerosis: a metaanalysis of case-control studies, J. Rheumatol, vol.34, pp.97-103, 2007.

E. C. Janowsky, L. L. Kupper, and B. S. Hulka, Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases, N. Engl. J. Med, vol.342, pp.781-790, 2000.

E. R. Volkmann, Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium. Arthritis & Rheumatology (Hoboken, N.J.), vol.68, pp.1483-1492, 2016.

K. Andréasson, Z. Alrawi, A. Persson, G. Jönsson, and J. Marsal, Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease, Arthritis Res. Ther, vol.18, p.278, 2016.

V. Viswanath, M. M. Phiske, and V. V. Gopalani, Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations, Indian J Dermatol, vol.58, pp.255-268, 2013.

M. Trojanowska, Cellular and molecular aspects of vascular dysfunction in systemic sclerosis, Nat Rev Rheumatol, vol.6, pp.453-460, 2010.

R. Sgonc, Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma, J. Clin. Invest, vol.98, pp.785-792, 1996.

B. J. Rabquer, The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1, Rheumatology (Oxford), vol.48, pp.734-740, 2009.

L. J. Ignarro, Endothelium-derived nitric oxide: actions and properties, FASEB J, vol.3, pp.31-36, 1989.

R. Vancheeswaran, Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction?, J. Rheumatol, vol.21, pp.1838-1844, 1994.

M. Cutolo, C. Pizzorni, M. E. Secchi, A. Sulli, and . Capillaroscopy, Best Pract Res Clin Rheumatol, vol.22, pp.1093-1108, 2008.

J. Avouac, Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis, Arthritis Res. Ther, vol.15, p.55, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00827903

N. Del-papa, Bone marrow endothelial progenitors are defective in systemic sclerosis, Arthritis Rheum, vol.54, pp.2605-2615, 2006.

A. Benyamine, Increased serum levels of fractalkine and mobilisation of CD34+CD45-endothelial progenitor cells in systemic sclerosis, Arthritis Res. Ther, vol.19, p.60, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01777909

M. Hebbar, Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis, Arthritis Rheum, vol.43, pp.889-893, 2000.

R. F. Macko, Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation, J. Rheumatol, vol.29, pp.2565-2570, 2002.

L. Van-bon, Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis, N. Engl. J. Med, vol.370, pp.433-443, 2014.

M. Manetti, Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis, Circ. Res, vol.109, pp.14-26, 2011.

M. Kuwana, Y. Okazaki, H. Yasuoka, Y. Kawakami, and Y. Ikeda, Defective vasculogenesis in systemic sclerosis, Lancet, vol.364, pp.603-610, 2004.

M. Y. Mok, Low circulating level of CD133+KDR+cells in patients with systemic sclerosis, Clin. Exp. Rheumatol, vol.28, pp.19-25, 2010.

F. V. Andrigueti, M. I. Arismendi, P. C. Ebbing, and C. Kayser, Decreased numbers of endothelial progenitor cells in patients in the early stages of systemic sclerosis, Microvasc. Res, vol.98, pp.82-87, 2015.

M. Kuwana and Y. Okazaki, Brief report: impaired in vivo neovascularization capacity of endothelial progenitor cells in patients with systemic sclerosis. Arthritis & Rheumatology (Hoboken, N.J.), vol.66, pp.1300-1305, 2014.

S. Zhu, Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells, Circulation, vol.118, pp.2156-2165, 2008.

M. Manetti, Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis, 2017.

S. A. Jimenez, Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis, ISRN Rheumatol, p.835948, 2013.

E. Pardali, G. Sanchez-duffhues, M. C. Gomez-puerto, and P. Ten-dijke, TGF-?-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases, Int J Mol Sci, vol.18, 2017.

T. Z. Kirk, M. E. Mark, C. C. Chua, B. H. Chua, and M. D. Mayes, Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1, J. Biol. Chem, vol.270, pp.3423-3428, 1995.

A. Van-caam, M. Vonk, F. Van-den-hoogen, P. Van-lent, and P. Van-der-kraan, Unraveling SSc Pathophysiology, The Myofibroblast. Front Immunol, vol.9, p.2452, 2018.

Y. Mori, S. Chen, and J. Varga, Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts, Arthritis Rheum, vol.48, pp.1964-1978, 2003.

A. Servettaz,

, Presse Med, vol.35, pp.1903-1915, 2006.

T. Kawakami, Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype, J. Invest. Dermatol, vol.110, pp.47-51, 1998.

M. Kubo, H. Ihn, K. Yamane, and K. Tamaki, Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma, Arthritis Rheum, vol.44, pp.731-734, 2001.

C. Fertin, Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents, Cell Mol Biol, vol.37, pp.823-829, 1991.

C. J. Ong, A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice, Cell Immunol, vol.196, pp.60-68, 1999.

M. L. Biondi, B. Marasini, E. Bianchi, and A. Agostoni, Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon, Int J Cardiol, vol.19, pp.335-339, 1988.

C. Dees, Platelet-derived serotonin links vascular disease and tissue fibrosis, J Exp Med, vol.208, pp.961-972, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00589662

A. Servettaz, Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis, Am. J. Pathol, vol.177, pp.187-196, 2010.

K. Kuroda and H. Shinkai, Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis, Arch. Dermatol. Res, vol.289, pp.567-572, 1997.

S. Svegliati, Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts, J Biol Chem, vol.280, pp.36474-36482, 2005.

B. Maurer, MicroRNA-29, a key regulator of collagen expression in systemic sclerosis, Arthritis Rheum, vol.62, pp.1733-1743, 2010.

N. Honda, miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin beta3, Am J Pathol, vol.182, pp.206-216, 2013.

K. Makino, The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma, J Immunol, vol.190, pp.3905-3915, 2013.

B. M. Kraling, G. G. Maul, and S. A. Jimenez, Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages, Pathobiology, vol.63, pp.48-56, 1995.

O. Ishikawa and H. Ishikawa, Macrophage infiltration in the skin of patients with systemic sclerosis, J Rheumatol, vol.19, pp.1202-1206, 1992.

Y. Y. Ho, D. Lagares, A. M. Tager, and M. Kapoor, Fibrosis--a lethal component of systemic sclerosis, Nat Rev Rheumatol, vol.10, pp.390-402, 2014.

J. R. Seibold, R. C. Giorno, and H. N. Claman, Dermal mast cell degranulation in systemic sclerosis, Arthritis Rheum, vol.33, pp.1702-1709, 1990.

A. D. Roumm, T. L. Whiteside, T. A. Medsger, and G. P. Rodnan, Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations, Arthritis Rheum, vol.27, pp.645-653, 1984.

C. Mavalia, Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis, Am J Pathol, vol.151, pp.1751-1758, 1997.

G. Valentini, Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation, J Clin Immunol, vol.21, pp.210-217, 2001.

M. Hasegawa, M. Fujimoto, K. Kikuchi, and K. Takehara, Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis, J Rheumatol, vol.24, pp.328-332, 1997.

S. Mehra, J. Walker, K. Patterson, and M. J. Fritzler, Autoantibodies in systemic sclerosis, Autoimmun Rev, vol.12, pp.340-354, 2013.

T. Matsushita, Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes, Arthritis Rheum, vol.54, pp.192-201, 2006.

S. Bosello, B cells in systemic sclerosis: a possible target for therapy, Autoimmun Rev, vol.10, pp.624-630, 2011.

Y. Shima, The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab, Rheumatology (Oxford), vol.49, pp.2408-2412, 2010.

S. Bhattacharyya, J. Wei, and J. Varga, Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities, Nat Rev Rheumatol, vol.8, pp.42-54, 2011.

, Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, Arthritis Rheum, vol.23, pp.581-590, 1980.

E. C. Leroy, Scleroderma (systemic sclerosis): classification, subsets and pathogenesis, J. Rheumatol, vol.15, pp.202-205, 1988.

C. P. Denton and D. Khanna, Systemic sclerosis, Lancet, vol.390, pp.1685-1699, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02042780

E. C. Leroy and T. A. Medsger, Criteria for the classification of early systemic sclerosis, J. Rheumatol, vol.28, pp.1573-1576, 2001.

F. Van-den-hoogen, classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative, Ann. Rheum. Dis, vol.72, pp.1747-1755, 2013.

T. Czompoly, D. Simon, L. Czirjak, and P. Nemeth, Anti-topoisomerase I autoantibodies in systemic sclerosis, Autoimmun Rev, vol.8, pp.692-696, 2009.

F. Perosa, Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin, Autoimmun Rev, vol.15, pp.102-109, 2016.

V. Sobanski, Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis, Arthritis Rheumatol, vol.66, pp.407-417, 2014.

F. Rannou, Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Arthritis Rheum, vol.57, pp.94-102, 2007.

G. Magalon, Regenerative Approach to Scleroderma with Fat Grafting, Clin Plast Surg, vol.42, pp.353-364, 2015.

A. U. Wells, V. Steen, and G. Valentini, Pulmonary complications: one of the most challenging complications of systemic sclerosis, Rheumatology (Oxford), vol.48, pp.40-44, 2009.

G. Bussone and L. Mouthon, Interstitial lung disease in systemic sclerosis, Autoimmun Rev, vol.10, pp.248-255, 2011.

L. Pavec, J. Launay, D. Mathai, S. C. Hassoun, P. M. Humbert et al., Scleroderma lung disease, Clin Rev Allergy Immunol, vol.40, pp.104-116, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01573783

E. Hachulla, The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France, Arthritis Rheum, vol.60, pp.1831-1839, 2009.

D. Launay, Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era, Ann Rheum Dis, vol.72, pp.1940-1946, 2013.

S. Sitia, Cardiovascular involvement in systemic autoimmune diseases, Autoimmun Rev, vol.8, pp.281-286, 2009.

L. Mouthon, Scleroderma renal crisis: a rare but severe complication of systemic sclerosis, Clin Rev Allergy Immunol, vol.40, pp.84-91, 2011.

G. Bussone, A. Bérezné, V. Pestre, L. Guillevin, and L. Mouthon, The scleroderma kidney: progress in risk factors, therapy, and prevention, Curr Rheumatol Rep, vol.13, pp.37-43, 2011.

G. Gyger and M. Baron, Systemic Sclerosis: Gastrointestinal Disease and Its Management, Rheum. Dis. Clin. North Am, vol.41, pp.459-473, 2015.

K. P. Tiev and J. Cabane, Digestive tract involvement in systemic sclerosis, Autoimmun Rev, vol.11, pp.68-73, 2011.

E. Rosato, Nutritional status measured by BMI is impaired and correlates with left ventricular mass in patients with systemic sclerosis, Nutrition, vol.30, pp.204-209, 2014.

V. Codullo, Disease-related malnutrition in systemic sclerosis: evidences and implications, Clin Exp Rheumatol, vol.33, pp.190-194, 2015.

B. Doerfler, Medical Nutrition Therapy for Patients With Advanced Systemic Sclerosis (MNT PASS): A Pilot Intervention Study, JPEN J Parenter Enteral Nutr, vol.41, pp.678-684, 2017.

E. Harrison, A. L. Herrick, M. Dibb, J. T. Mclaughlin, and S. Lal, Long-term outcome of patients with systemic sclerosis requiring home parenteral nutrition, Clin Nutr, vol.34, pp.991-996, 2015.

Z. Stanga, Home parenteral nutrition is beneficial in systemic sclerosis patients with gastrointestinal dysfunction, Scand J Rheumatol, vol.45, pp.32-35, 2016.

P. J. Clements, Y. Allanore, D. Khanna, M. Singh, and D. E. Furst, Arthritis in systemic sclerosis: systematic review of the literature and suggestions for the performance of future clinical trials in systemic sclerosis arthritis, Semin Arthritis Rheum, vol.41, pp.801-814, 2012.

L. Scussel-lonzetti, Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival, Medicine (Baltimore), vol.81, pp.154-167, 2002.

E. N. Le, F. M. Wigley, A. A. Shah, F. Boin, and L. K. Hummers, Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis, Ann. Rheum. Dis, vol.70, pp.1104-1107, 2011.

J. E. Pope, A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma, Arthritis Rheum, vol.44, pp.1351-1358, 2001.

S. T. Panopoulos, Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study, Lung, vol.191, pp.483-489, 2013.

G. Sircar, R. P. Goswami, D. Sircar, A. Ghosh, and P. Ghosh, Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial, Rheumatology (Oxford), vol.57, pp.2106-2113, 2018.

K. Didier,

, Rev Med Interne, 2019.

G. K. Lam, L. K. Hummers, A. Woods, and F. M. Wigley, Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease, J. Rheumatol, vol.34, pp.1636-1637, 2007.

D. Khanna, Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate), Ann. Rheum. Dis, vol.77, pp.212-220, 2018.

L. M. Rice, Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients, J. Clin. Invest, vol.125, pp.2795-2807, 2015.

J. K. Gordon, Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. Arthritis & Rheumatology, vol.70, pp.308-316, 2018.

R. Spiera, OP0126 A phase 2 study of safety and efficacy of anabasum (JBT-101) in systemic sclerosis, Annals of the Rheumatic Diseases, vol.76, pp.105-105, 2017.

O. Distler, Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease, N. Engl. J. Med, vol.380, pp.2518-2528, 2019.

O. Distler, RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis, Respir Med, vol.122, issue.1, pp.14-17, 2017.

J. Magalon, Thérapie cellulaire et cellules souches en, Revue Francophone, pp.34-43, 2018.

J. A. Thomson, Embryonic stem cell lines derived from human blastocysts, Science, vol.282, pp.1145-1147, 1998.

L. M. Hoffman and M. K. Carpenter, Characterization and culture of human embryonic stem cells, Nat. Biotechnol, vol.23, pp.699-708, 2005.

J. B. Gurdon, The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles, J Embryol Exp Morphol, vol.10, pp.622-640, 1962.

K. Takahashi, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, vol.131, pp.861-872, 2007.

A. J. Friedenstein, J. F. Gorskaja, and N. N. Kulagina, Fibroblast precursors in normal and irradiated mouse hematopoietic organs, Exp. Hematol, vol.4, pp.267-274, 1976.

S. Roux, J. Leotot, N. Chevallier, P. Bierling, and H. Rouard,

, Transfus Clin Biol, vol.18, pp.1-12, 2011.

J. E. Till and E. A. Mcculloch, A direct measurement of the radiation sensitivity of normal mouse bone marrow cells, Radiat. Res, vol.14, pp.213-222, 1961.

M. Binks, Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease, Ann. Rheum. Dis, vol.60, pp.577-584, 2001.

P. De-buys, D. Khanna, and D. E. Furst, Hemopoietic stem cell transplantation in rheumatic diseases--an update, Autoimmun Rev, vol.4, pp.442-449, 2005.

G. Pugnet, Indications et suivi des autogreffes de cellules souches hématopoïétiques dans les maladies auto-immunes et auto-inflammatoires : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC), Bulletin du Cancer, vol.104, pp.169-180, 2017.

T. Alexander, Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system, Blood, vol.113, pp.214-223, 2009.

D. Farge, Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis, Arthritis Rheum, vol.52, pp.1555-1563, 2005.

S. Abrahamsson and P. A. Muraro, Immune re-education following autologous hematopoietic stem cell transplantation, Autoimmunity, vol.41, pp.577-584, 2008.

J. A. Snowden, Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation, Bone Marrow Transplant, vol.47, pp.770-790, 2012.

P. A. Muraro, Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis, Nat Rev Neurol, vol.13, pp.391-405, 2017.

M. K. Talekar, Immune Reconstitution After Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cell Transplantation for the, Pediatric Hematologist/Oncologist, 2018.

H. Tsukamoto, Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells, Rheumatology (Oxford), vol.50, pp.944-952, 2011.

J. Baraut, Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study, Bone Marrow Transplant, vol.49, pp.349-354, 2014.

L. Michel, Evolution of serum cytokine profile after hematopoietic stem cell transplantation in systemic sclerosis patients, Bone Marrow Transplant, vol.51, pp.1146-1149, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01704546

K. M. Sullivan, Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma, N. Engl. J. Med, vol.378, pp.35-47, 2018.

J. C. Massey, I. J. Sutton, D. D. Ma, and J. J. Moore, Regenerating Immunotolerance in Multiple Sclerosis with, Autologous Hematopoietic Stem Cell Transplant. Front Immunol, vol.9, p.410, 2018.

G. Slobodin and D. Rimar, Regulatory T Cells in Systemic Sclerosis: a Comprehensive Review, Clin Rev Allergy Immunol, vol.52, pp.194-201, 2017.

E. M. Delemarre, Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells, Blood, vol.127, pp.91-101, 2016.

S. T. Roord, Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells, Blood, vol.111, pp.5233-5241, 2008.

J. F. Swart, Haematopoietic stem cell transplantation for autoimmune diseases, Nat Rev Rheumatol, vol.13, pp.244-256, 2017.

R. K. Burt, Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial, Lancet, vol.378, pp.498-506, 2011.

J. M. Van-laar, Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial, JAMA, vol.311, pp.2490-2498, 2014.

N. Del-papa, F. Pignataro, E. Zaccara, W. Maglione, and A. Minniti, Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis, Front Immunol, vol.9, p.2390, 2018.

M. C. Oliveira, Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?, Bone Marrow Transplantation, vol.51, pp.501-505, 2016.

J. Moore, A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis, Arthritis Rheum, vol.46, pp.2301-2309, 2002.

M. Dominici, Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, Cytotherapy, vol.8, pp.315-317, 2006.

X. Liang, Y. Ding, Y. Zhang, H. Tse, and Q. Lian, Paracrine Mechanisms of Mesenchymal Stem Cell-Based Therapy: Current Status and Perspectives, Cell Transplant, vol.23, pp.1045-1059, 2014.

S. C. Abreu, D. J. Weiss, and P. R. Rocco, Extracellular vesicles derived from mesenchymal stromal cells: a therapeutic option in respiratory diseases?, Stem Cell Res Ther, vol.7, p.53, 2016.

J. L. Spees, R. H. Lee, and C. A. Gregory, Mechanisms of mesenchymal stem/stromal cell function, Stem Cell Res Ther, vol.7, p.125, 2016.

D. S. Krause, Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell, Cell, vol.105, pp.369-377, 2001.

N. D. Theise, On experimental design and discourse in plasticity research, Stem Cell Rev, vol.1, pp.9-13, 2005.

J. Rehman, Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells, Circulation, vol.109, pp.1292-1298, 2004.

H. Nakagami, Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells, Arterioscler. Thromb. Vasc. Biol, vol.25, pp.2542-2547, 2005.

V. Planat-benard, Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives, Circulation, vol.109, pp.656-663, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00409575

A. De-luca, Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells, J. Cell. Physiol, vol.226, pp.2131-2138, 2011.

P. R. Crisostomo, Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B-but not JNK-dependent mechanism, Am. J. Physiol, vol.294, pp.675-682, 2008.

A. Liew and T. O'brien, Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia, Stem Cell Res Ther, vol.3, p.28, 2012.

K. Ni, PD-1/PD-L1 Pathway Mediates the Alleviation of Pulmonary Fibrosis by Human Mesenchymal Stem Cells in Humanized Mice, Am. J. Respir. Cell Mol. Biol, vol.58, pp.684-695, 2018.

C. Donizetti-oliveira, Adipose tissue-derived stem cell treatment prevents renal disease progression, Cell Transplant, vol.21, pp.1727-1741, 2012.

Y. Wu, Bone marrow-derived mesenchymal stem cell attenuates skin fibrosis development in mice, Int Wound J, vol.11, pp.701-710, 2014.

J. A. Horton, Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation, Stem Cells, vol.31, pp.2231-2241, 2013.

A. T. Maria, Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis, J. Autoimmun, vol.70, pp.31-39, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01834289

W. Chen, Adipose tissue-derived stem cells ameliorates dermal fibrosis in a mouse model of scleroderma, Asian Pac J Trop Med, vol.10, pp.52-56, 2017.

L. Blanc and K. , Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, Lancet, vol.363, pp.1439-1441, 2004.

A. Bartholomew, Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo, Exp. Hematol, vol.30, pp.42-48, 2002.

D. Nicola and M. , Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli, Blood, vol.99, pp.3838-3843, 2002.

A. J. Nauta and W. E. Fibbe, Immunomodulatory properties of mesenchymal stromal cells, Blood, vol.110, pp.3499-3506, 2007.

W. T. Tse, J. D. Pendleton, W. M. Beyer, M. C. Egalka, and E. C. Guinan, Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation, Transplantation, vol.75, pp.389-397, 2003.

H. Mohammadpour, A. A. Pourfathollah, M. N. Zarif, and M. T. Tahoori, TNF-? modulates the immunosuppressive effects of MSCs on dendritic cells and T cells, Int. Immunopharmacol, vol.28, pp.1009-1017, 2015.

M. M. Rosado, Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells, Stem Cells Dev, vol.24, pp.93-103, 2015.

P. Hwu, Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation, J. Immunol, vol.164, pp.3596-3599, 2000.

S. Aggarwal and M. F. Pittenger, Human mesenchymal stem cells modulate allogeneic immune cell responses, Blood, vol.105, pp.1815-1822, 2005.

K. Akiyama, Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FASmediated T cell apoptosis, Cell Stem Cell, vol.10, pp.544-555, 2012.

L. Blanc, K. Mougiakakos, and D. , Multipotent mesenchymal stromal cells and the innate immune system, Nat. Rev. Immunol, vol.12, pp.383-396, 2012.

S. Guiducci, Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report, Ann. Intern. Med, vol.153, pp.650-654, 2010.

M. Christopeit, Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L, Leukemia, vol.22, pp.1062-1064, 2008.

G. Keyszer, Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases, Arthritis Rheum, vol.63, pp.2540-2542, 2011.

H. Zhang, Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis, Arthritis Res. Ther, vol.19, p.165, 2017.

Z. Szekanecz, Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects, Clin. Rheumatol, vol.28, pp.347-350, 2009.

G. Szúcs, S. Szamosi, M. Aleksza, K. Veres, and P. Soltész,

, Orv Hetil, vol.144, pp.2213-2217, 2003.

J. Liang, Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study, Stem Cell Res Ther, vol.9, p.312, 2018.

D. Farge, Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases, Haematologica, vol.95, pp.284-292, 2010.

T. Asahara, Isolation of putative progenitor endothelial cells for angiogenesis, Science, vol.275, pp.964-967, 1997.

T. Asahara, Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization, Circ Res, vol.85, pp.221-228, 1999.

J. Tongers, J. G. Roncalli, and D. W. Losordo, Role of endothelial progenitor cells during ischemiainduced vasculogenesis and collateral formation, Microvasc Res, vol.79, pp.200-206, 2010.

C. Kalka, Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization, Proc Natl Acad Sci U S A, vol.97, pp.3422-3427, 2000.

G. C. Schatteman, H. D. Hanlon, C. Jiao, S. G. Dodds, and B. A. Christy, Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice, J Clin Invest, vol.106, pp.571-578, 2000.

V. Zaccone, Focus on biological identity of endothelial progenitors cells, Eur Rev Med Pharmacol Sci, vol.19, pp.4047-4063, 2015.

M. C. Yoder, Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals, Blood, vol.109, pp.1801-1809, 2007.

D. A. Ingram, Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells, Blood, vol.105, pp.2783-2786, 2005.

P. J. Psaltis and R. D. Simari, Vascular wall progenitor cells in health and disease, Circ. Res, vol.116, pp.1392-1412, 2015.

M. H. Fonseca-alaniz, J. Takada, M. I. Alonso-vale, and F. B. Lima, Adipose tissue as an endocrine organ: from theory to practice, J Pediatr (Rio J), vol.83, pp.192-203, 2007.

D. L. Crandall, G. J. Hausman, and J. G. Kral, A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives, Microcirculation, vol.4, pp.211-232, 1997.

I. Nseir, Use of adipose tissue and stromal vascular fraction in hand surgery, Orthop Traumatol Surg Res, vol.103, pp.927-932, 2017.

P. A. Zuk, Multilineage cells from human adipose tissue: implications for cell-based therapies, Tissue Eng, vol.7, pp.211-228, 2001.

J. Bank, S. M. Fuller, G. I. Henry, and L. S. Zachary, Fat grafting to the hand in patients with Raynaud phenomenon: a novel therapeutic modality, Plast. Reconstr. Surg, vol.133, pp.1109-1118, 2014.

N. Del-papa, Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis, Cell Transplant, vol.24, pp.2297-2305, 2015.

N. Del-papa, Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study, Arthritis Res. Ther, vol.21, p.7, 2019.

G. Consorti, R. Tieghi, and L. C. Clauser, Frontal linear scleroderma: long-term result in volumetric restoration of the fronto-orbital area by structural fat grafting, J Craniofac Surg, vol.23, pp.263-265, 2012.

M. R. Roh, J. Y. Jung, and K. Y. Chung, Autologous fat transplantation for depressed linear scleroderma-induced facial atrophic scars, Dermatol Surg, vol.34, pp.1659-1665, 2008.

N. Sautereau, Efficacy of Autologous Microfat Graft on Facial Handicap in Systemic Sclerosis Patients, Plast Reconstr Surg Glob Open, vol.4, p.660, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01455651

N. Del-papa, Autologous fat grafting in the treatment of fibrotic perioral changes in patients with systemic sclerosis, Cell Transplant, vol.24, pp.63-72, 2015.

F. Virzi, Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patients, Stem Cell Res Ther, vol.8, p.236, 2017.

C. Philandrianos, Combined PRP and microfat graft for facial disability in systemic sclerosis, J Scleroderma Relat Disord, vol.2, pp.7-11, 2017.

P. Bourin, Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT), Cytotherapy, vol.15, pp.641-648, 2013.

X. Zhu, W. Shi, W. Tai, and F. Liu, The comparition of biological characteristics and multilineage differentiation of bone marrow and adipose derived Mesenchymal stem cells, Cell Tissue Res, vol.350, pp.277-287, 2012.

K. Yoshimura, Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stem/stromal cells, Aesthetic Plast Surg, vol.32, pp.56-57, 2008.

G. Rigotti, Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells, Plast Reconstr Surg, vol.119, pp.1423-1424, 2007.

D. O. Traktuev, Robust functional vascular network formation in vivo by cooperation of adipose progenitor and endothelial cells, Circ Res, vol.104, pp.1410-1420, 2009.

P. Bora and A. S. Majumdar, Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation, Stem Cell Res Ther, vol.8, p.145, 2017.

Y. Harada, Transplantation of freshly isolated adipose tissue-derived regenerative cells enhances angiogenesis in a murine model of hind limb ischemia, Biomed. Res, vol.34, pp.23-29, 2013.

J. Guo, Stromal vascular fraction: A regenerative reality? Part 2: Mechanisms of regenerative action, J Plast Reconstr Aesthet Surg, vol.69, pp.180-188, 2016.

S. Domergue, Comparison between Stromal Vascular Fraction and Adipose Mesenchymal Stem Cells in Remodeling Hypertrophic Scars, PLoS ONE, vol.11, p.156161, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01834377

Y. Hirose, Comparison of trophic factors secreted from human adipose-derived stromal vascular fraction with those from adipose-derived stromal/stem cells in the same individuals, Cytotherapy, vol.20, pp.589-591, 2018.

N. Serratrice, New fat-derived products for treating skin-induced lesions of scleroderma in nude mice, Stem Cell Res Ther, vol.5, 2014.

B. Granel, Safety, tolerability and potential efficacy of injection of autologous adiposederived stromal vascular fraction in the fingers of patients with systemic sclerosis: an openlabel phase I trial, Ann Rheum Dis, vol.74, pp.2175-2182, 2015.

A. Daumas, Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients, Curr Res Transl Med, vol.65, pp.40-43, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01792172

N. Scuderi, Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis, Cell Transplant, vol.22, pp.779-795, 2013.

M. G. Onesti, Improvement of Mouth Functional Disability in Systemic Sclerosis Patients over One Year in a Trial of Fat Transplantation versus Adipose-Derived Stromal Cells, Stem Cells Int, p.2416192, 2016.

F. C. Van-rhijn-brouwer, A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol, BMJ Open, vol.8, p.20479, 2018.

J. Magalon, Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis, Ann. Rheum. Dis, vol.78, pp.391-398, 2019.